Group One Trading
CRSP icon

Group One Trading’s CRISPR Therapeutics CRSP Stock Holding History

Group One Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.57M Buy
96,001
+2,047
+2% +$108K 0.01% 1370
2025
Q4 		$4.93M Sell
93,954
-3,288
-3% -$197K 0.01% 1503
2025
Q3 		$6.3M Buy
97,242
+91,530
+1,602% +$5.25M 0.01% 1285
2025
Q2 		$278K Buy
5,712
+5,440
+2,000% +$211K ﹤0.01% 4005
2025
Q1 		$9.26K Sell
272
-135,011
-100% -$5.72M ﹤0.01% 6313
2024
Q4 		$5.32M Buy
135,283
+42,449
+46% +$2M 0.01% 1124
2024
Q3 		$4.36M Buy
92,834
+24,344
+36% +$1.24M 0.01% 1104
2024
Q2 		$3.7M Buy
68,490
+44,937
+191% +$2.6M 0.01% 996
2024
Q1 		$1.61M Buy
+23,553
New +$1.69M 0.01% 1675
2023
Q4 		– Sell
-63,677
Closed -$3.52M – 7506
2023
Q3 		$2.89M Sell
63,677
-10,362
-14% -$535K 0.01% 1338
2023
Q2 		$4.16M Buy
74,039
+27,642
+60% +$1.57M 0.01% 1105
2023
Q1 		$2.1M Buy
46,397
+493
+1% +$23.9K 0.01% 1476
2022
Q4 		$1.87M Buy
45,904
+39,058
+571% +$2.07M ﹤0.01% 1886
2022
Q3 		$447K Sell
6,846
-128,901
-95% -$9.34M ﹤0.01% 3337
2022
Q2 		$8.25M Sell
135,747
-89,772
-40% -$5.28M 0.01% 976
2022
Q1 		$14.2M Sell
225,519
-253,278
-53% -$15.9M 0.01% 795
2021
Q4 		$36.3M Buy
478,797
+186,961
+64% +$16.3M 0.03% 408
2021
Q3 		$32.7M Sell
291,836
-107,911
-27% -$13.6M 0.04% 405
2021
Q2 		$64.7M Buy
399,747
+22,853
+6% +$2.78M 0.08% 197
2021
Q1 		$45.9M Buy
376,894
+309,254
+457% +$46.7M 0.07% 244
2020
Q4 		$10.4M Buy
+67,640
New +$7.99M 0.02% 790
2019
Q1 		– Sell
-2,346
Closed -$81.1K – 4888
2018
Q4 		$67K Sell
2,346
-34,728
-94% -$1.21M ﹤0.01% 3398
2018
Q3 		$1.64M Buy
37,074
+28,713
+343% +$1.5M 0.01% 1307
2018
Q2 		$491K Sell
8,361
-5,832
-41% -$332K ﹤0.01% 2303
2018
Q1 		$649K Buy
14,193
+12,932
+1,026% +$534K 0.01% 1842
2017
Q4 		$30K Buy
+1,261
New +$24K ﹤0.01% 3982

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Group One Trading's CRSP Position: Q1 2026 in Review

Group One Trading increased its CRISPR Therapeutics (CRSP) stake by 2.2% in Q1 2026, buying an estimated $108K and bringing the position to 96,001 shares worth $4.57M. The position accounts for 0.01% of the portfolio, ranked #1370.

Group One Trading first reported a position in CRSP in Q4 2017 and has held it in 26 quarters since. The position peaked at $64.7M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Group One Trading held 96,001 shares of CRISPR Therapeutics worth $4.57M as of Q1 2026.
  • Group One Trading bought 2,047 CRISPR Therapeutics shares in Q1 2026, an estimated $108K.
  • CRISPR Therapeutics made up 0.01% of Group One Trading's portfolio in Q1 2026, its #1370 holding.
  • Group One Trading first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 26 quarters since.
  • Group One Trading's CRISPR Therapeutics position peaked at $64.7M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.